Anvisa discusses this Wednesday the authorization of the production of medicinal cannabis by companies
The board of directors of the National Health Surveillance Agency ( Anvisa ) will meet on the afternoon of this Wednesday 13th to discuss, among other topics, the regulation of the cultivation of Cannabis sativa L , a species of plant with a low tetrahydrocannabinol (THC) content by companies for medicinal purposes .
The meeting takes place two months after the Superior Court of Justice (STJ) extended the deadline for the agency to discuss the matter. The original deadline expired on May 19, but Anvisa and the federal government requested an extension.
If approved by the health surveillance agency, cultivation by companies will be used to manufacture pharmaceutical or veterinary inputs.
The STJ decision that allowed the cultivation and planting of cannabis by companies was made in November 2024. The case involved an appeal by a biotechnology company, which sought, at the time, authorization to import seeds and cultivate industrial hemp in the country.
The issue was treated as having general repercussions, which means that all cases involving similar requests will be decided based on the same thesis.
The determination, which is important to note, applies to so-called industrial hemp ( hemp ), a variety of cannabis with a percentage of less than 0.3% THC, the psychoactive principle of marijuana.
CartaCapital For 30 years, the main reference in progressive journalism in Brazil.
Subscribe to our newsletter and receive an exclusive morning bulletin
After difficult years , we've returned to a Brazil that feels at least a little bit normal. This new normal, however, remains fraught with uncertainty . The Bolsonaro threat persists, and the appetites of the market and Congress continue to pressure the government. Abroad, the global rise of the far right and the brutality in Gaza and Ukraine risk imploding the fragile foundations of global governance.
CartaCapital doesn't receive support from banks or foundations. It survives solely on advertising and project sales, and contributions from its readers . And your support, our readers, is increasingly crucial .
Don't let Carta stop. If you value good journalism, help us keep fighting. Subscribe to the weekly edition of the magazine or contribute whatever you can.
Subscribe to our newsletter and receive an exclusive morning bulletin
CartaCapital
